Folotyn for Non-Hodgkin's Lymphoma Lancaster NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Lynn Marie Steinbrenneer
(716) 862-3191
3495 Bailey Ave
Buffalo, NY
THOMAS OCONNOR, MD
(716) 447-6100
2950 Elmwood Avenue
Buffalo, NY
Monica Buckley Spaulding, MD
716-829-2752
150 Parker Hall
Buffalo, NY
Lorna K Fitzpatrick, MD
219 Bryant St
Buffalo, NY
Philip L Mc Carthy, MD
716-845-8707
Buffalo, NY
Thom Loree
(716) 689-1901
Elm And Carlton St
Buffalo, NY
John Gibbs
(716) 845-2300
Elm And Carlton St
Buffalo, NY
CHARLES LEVEA, MD
(716) 845-2300
Elm And Carlton Street
Buffalo, NY
Lawrence Charles Olsen, MD
Buffalo, NY
Helen Koyu Chen, MD
716-898-5500
426 Grider St
Buffalo, NY
Data Provided by:
    

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Green Tea and Hematologic Malignancies Lancaster NY
Read more about Green Tea May Lower the Risk of Hematologic Malignancies.
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Lancaster NY